Asia PacificENPublic drug registration overview
China Pharmaceutical Registration Pathway
Market Overview Market profile: Drug registration in China is led by NMPA, with CDE conducting core technical review. Innovative drugs, modified new drugs, generics, biologics, and...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: China Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Regulatory maturity: High. China has adopted substantial ICH-aligned practices and continues review reform.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Market profile: Drug registration in China is led by NMPA, with CDE conducting core technical review. Innovative drugs, modified new drugs, generics, biologics, and foreign-manufactured drugs all follow defined categories and dossier expectations.
- Regulatory maturity: High. China has adopted substantial ICH-aligned practices and continues review reform.
- Core decision: First confirm product category, clinical trial requirements, foreign-manufactured status, and whether priority review, breakthrough therapy, or conditional approval may apply.
Regulators
- Authority: National Medical Products Administration (NMPA)
- Technical review: Center for Drug Evaluation (CDE), NMPA
- Related bodies: NIFDC, inspection center, pharmacovigilance center, pharmacopoeia commission, and others
Product Types and Review Pathways
| Type | Common path | Key evidence |
|---|---|---|
| Chemical innovative drug | IND + marketing authorisation application | CMC, pharmacology/toxicology, and full clinical evidence |
| Chemical generic | Marketing application, often with consistency and BE work | Quality studies, reference product, BE or waiver rationale |
| Biologic | IND + marketing authorisation application | Quality, nonclinical, clinical, and batch consistency evidence |
| Foreign-manufactured drug | Imported registration under detailed category | Overseas approval, manufacturing quality, clinical and bridging evidence |
| Traditional Chinese medicine | Category-specific TCM application | Traditional use, quality, nonclinical, and clinical evidence mix |
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.